Related Experiment Videos
Targeting interleukin-6 in pediatric rheumatic diseases
1IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy. fabrizio.debenedetti@opbg.net
Current Opinion in Rheumatology
|July 14, 2009
Summary
Interleukin-6 (IL-6) plays a key role in immune responses. Tocilizumab, an IL-6 inhibitor, shows promise in treating pediatric rheumatic diseases, particularly systemic juvenile idiopathic arthritis (s-JIA).
Area of Science:
- Immunology
- Rheumatology
- Pharmacology
Background:
- Interleukin-6 (IL-6) is a critical cytokine in immune and inflammatory processes.
- Tocilizumab is the only approved inhibitor targeting the IL-6 pathway.
- Pediatric rheumatic diseases encompass a range of chronic inflammatory conditions affecting children.
Purpose of the Study:
- To review current data on IL-6's role in immunity and inflammation.
- To detail the mechanism of action and safety profile of tocilizumab.
- To discuss the efficacy of IL-6 inhibition in pediatric rheumatic diseases.
Main Methods:
- Literature review of recent studies on IL-6.
- Analysis of clinical trial data for tocilizumab in adult and pediatric populations.
- Evaluation of safety and efficacy data, including withdrawal and open-label studies.
Main Results:
- Updated understanding of IL-6 effects on T and B cells.
- Tocilizumab demonstrates a robust safety profile in adult rheumatoid arthritis trials.
- Significant efficacy observed in systemic juvenile idiopathic arthritis (s-JIA) and potential in other JIA subtypes.
Conclusions:
- IL-6 targeted therapy is effective for chronic inflammatory diseases.
- Long-term tocilizumab data are needed, but the risk/benefit appears favorable for s-JIA.
- Biomarker identification is crucial for personalized biologic therapy selection.
Related Concept Videos
01:24T Cell Types and Functions
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
01:20The JAK-STAT Signaling Pathway
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:21Rheumatic Heart Disease III: Medical Management
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...